^
Association details:
Biomarker:ER positive
Cancer:HER2 Negative Breast Cancer
Drug:ZEN-3694 (BET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer

Published date:
05/15/2020
Excerpt:
14 breast cancer PDXs (10 ER+/HER2- and 4 ER+/HER2+) that were resistant to CDK4/6i in vivo were treated with ZEN-3694, a selective BET inhibitor currently in clinical development. Nine of the PDXs were sensitive to BET inhibition in monotherapy (65%).
DOI:
10.1158/1538-7445.AM2020-1282